Medical treatment of tuberculosis-update 2011;Medikamentöse therapie der tuberkulose-update 2011

Therapeutische Umschau

Volumn 68, Issue 7, 2011, Pages 395-401

  von Groote Bidlingmaier, Florian ^a   Diacon, Andreas H ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

DRUG SENSITIVITY; REVIEW; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; INTERNATIONALITY; MICROBIAL SENSITIVITY TESTS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 79960064818     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000183     Document Type: Review

References (28)

1. World Health Organization. Global tuberculosis control. A short update to the 2009 report. Geneva, Switzerland 2009. WHO/HTM/TB/2009.426.
2. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, Switzerland 2010. WHO/ HTM/TB/2010.3.
3. www.who.int, accessed 07/01/2011.
4. Handbuch Tuberkulose, Hrsg. Lungenliga Schweiz und Bundesamt für Gesundheit. 2007.
5. Bartacek A, Schutt D, Panosch B, Borek M. Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13: 760-766.
6. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
7. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
8. World Health Organization. Treatment of tuberculosis: guidelines - 4thed. WHO/HTM/TB/2009.420. WHO 2010.
9. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847.
10. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, et al. Ac- quired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356.
11. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, et al. Efficacy of a 6 vs. a 9-month Intermittent Treatment Regimen in HIV-infected TB Patients: A Randomized Clinical Trial. Am J Respir Crit Care Med 2010; 181: 743-751.
12. Hong Kong Chest Service / British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
13. Hong Kong Chest Service / British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month threetimes- weekly regimens for smearpositive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143: 700-706.
14. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177: 1391-1396.
15. British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis: a controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976; 2: 1102-1104.
16. Slutkin G, Schecter GF, Hopewelll PC. The results of 9-month isoniazid- rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. Am Rev Respir Dis 1988; 138: 1622-1624.
17. Combs DL, O'Brien RJ, Geiter L. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity and acceptability; the report of final results. Ann Intern Med 1990; 112: 397-406.
18. American Thoracic Society / Centers for Disease Control and Prevention / Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
19. Espinal MA et al. Determinants of drug-resistant tuberculosis: analysis of 11 coun tries. Int J Tuberc Lung Dis 2001, 5: 887-893.
20. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.394).
21. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
22. Caminero J A. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12: 869-877.
23. Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10: 802-807.
24. Hanif M, Malik S, Dhingra VK. Acquired drug resistance pattern in tuberculosis cases at the State Tuberculosis Centre, Delhi, India. Int J Tuberc Lung Dis 2009; 13: 74-78.
25. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
26. Diacon AH, Pym A, Grobusch M, et al. The diarylquinolone TMC207 for drug-resistant tuberculosis. N Engl J Med. 2009 Jun 4; 360(23): 2397-2405.
27. Diacon AH, Dawson R, Hanekom M, et al. Early Bactericidal Activity of OPC-67683 in Smear-Positive Pulmonary Tuberculosis Patients. IJTLD. 2011. In press.
28. Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-490.